BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24473349)

  • 1. [Regulation and disorders of calcium and phosphate metabolism].
    Michigami T
    Clin Calcium; 2014 Feb; 24(2):169-75. PubMed ID: 24473349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenic role of Fgf23 in Dmp1-null mice.
    Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
    Michigami T
    Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in understanding of phosphate homeostasis and related disorders.
    Michigami T
    Endocr J; 2022 Aug; 69(8):881-896. PubMed ID: 35831119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralized tissues in hypophosphatemic rickets.
    Robinson ME; AlQuorain H; Murshed M; Rauch F
    Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1).
    Bai X; Levental M; Karaplis AC
    J Clin Endocrinol Metab; 2022 Sep; 107(10):2777-2783. PubMed ID: 35896139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23.
    Fukumoto S
    Intern Med; 2008; 47(5):337-43. PubMed ID: 18310961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.
    Karaplis AC; Bai X; Falet JP; Macica CM
    Endocrinology; 2012 Dec; 153(12):5906-17. PubMed ID: 23038738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
    Quarles LD
    Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-fibroblast growth factor 23 antibody therapy.
    Fukumoto S
    Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):346-51. PubMed ID: 24848934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.
    Gattineni J; Baum M
    Pediatr Nephrol; 2010 Apr; 25(4):591-601. PubMed ID: 19669798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 23 and its receptors.
    Yu X; White KE
    Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rickets/Osteomalacia. FGF23-related hypophosphatemic rickets/osteomalacia.].
    Fukumoto S
    Clin Calcium; 2018; 28(10):1313-1317. PubMed ID: 30269112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bone and Calcium Research Update 2015. Novel treatment for FGF23-related hypophosphatemic diseases].
    Fukumoto S
    Clin Calcium; 2015 Jan; 25(1):37-44. PubMed ID: 25530521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
    Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
    Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [FGF23-related hypophosphatemic rickets/osteomalacia].
    Ito N; Fukumoto S
    Clin Calcium; 2007 Oct; 17(10):1514-20. PubMed ID: 17906402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical aspect of recent progress in phosphate metabolism. The pathophysiology of diseases caused by aberrant actions of FGF23].
    Shimizu Y; Fukumoto S
    Clin Calcium; 2009 Jun; 19(6):802-7. PubMed ID: 19483274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical aspect of recent progress in phosphate metabolism. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23)].
    Endo I
    Clin Calcium; 2009 Jun; 19(6):815-20. PubMed ID: 19483276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism.
    Feng JQ; Ward LM; Liu S; Lu Y; Xie Y; Yuan B; Yu X; Rauch F; Davis SI; Zhang S; Rios H; Drezner MK; Quarles LD; Bonewald LF; White KE
    Nat Genet; 2006 Nov; 38(11):1310-5. PubMed ID: 17033621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.